Core Insights - Haiprui (002399.SZ) reported its Q3 2025 results on October 31, 2025, highlighting significant institutional investor holdings [1] Institutional Holdings - As of October 30, 2025, seven institutional investors disclosed holding a total of 1 billion shares of Haiprui, representing 68.14% of the company's total equity [1] - The institutional investor group includes Shenzhen Lerun Technology Co., Ltd., Gongqingcheng Jintian Soil Investment Partnership (Limited Partnership), Gongqingcheng Water Droplet Stone Investment Partnership (Limited Partnership), Gongqingcheng Feilai Stone Investment Co., Ltd., Shenzhen Haiprui Pharmaceutical Co., Ltd. - Second Employee Stock Ownership Plan, Hong Kong Central Clearing Limited, and Shenzhen Haiprui Pharmaceutical Group Co., Ltd. - Third Employee Stock Ownership Plan [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 0.44 percentage points [1] Public Fund Activity - In this period, 92 public funds were not disclosed compared to the previous quarter, including Southern CSI 1000 ETF, Huaxia CSI 1000 ETF, GF CSI 1000 ETF, GF CSI All-Index Medical and Health ETF, and Fortune CSI 1000 ETF [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings compared to the previous period, with a slight increase in shareholding percentage [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002399 证券简称：海普瑞 公告编号：2025-030 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 （二） 非经常性损益项目和金额 R适用 □不适用 单位：元 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 R否 其他符合非经常性损益定义的损益项目的具体情况： □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公 ...

格隆汇10月30日丨海普瑞(002399.SZ)发布公告，2025年前三季度，实现营业收入41.94亿元，同比增加 3.09%；归属于上市公司股东的净利润5.54亿元，同比减少29.04%；归属于上市公司股东的扣除非经常 性损益的净利润5.52亿元，同比增加28.69%；基本每股收益0.3773元。 ...

智通财经APP讯，海普瑞(09989)发布2025年第三季度报告，截止2025年9月30日止9个月，该公司取得营 业收入41.94亿元人民币，同比增加3.09%;归属于上市公司股东的净利润5.54亿元，同比减少29.04%;基 本每股收益0.3773元。 ...

Core Insights - The company reported a revenue of approximately 4.194 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 3.09% [1] - The net profit attributable to shareholders of the listed company was approximately 554 million yuan, showing a year-on-year decrease of 29.04% [1] Financial Performance - Revenue for the first three quarters of 2025: 4.194 billion yuan, up 3.09% year-on-year [1] - Net profit for the same period: 554 million yuan, down 29.04% year-on-year [1]

格隆汇10月30日丨海普瑞(09989.HK)发布公告，2025年前三季度，实现营业收入41.94亿元(人民币，下 同)，同比增加3.09%；归属于上市公司股东的净利润5.54亿元，同比减少29.04%；归属于上市公司股东 的扣除非经常性损益的净利润5.52亿元，同比增加28.69%；基本每股收益0.3773元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） 2025年第三季度報告 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記 載、誤導性陳述或重大遺漏。 本公告乃根據證券及期貨條例（香港法例第571章）第XIVA部及香港聯合交易所有 限公司證券上市規則第13.09條及第13.10B條而發表。 以下為深圳市海普瑞藥業集團股份有限公司（「本公司」或「公司」或「海普瑞」，連 同其附屬公司稱為「本集團」或「我們」）截止2025年9月30日止九個月（「報告期」）的 二零二五年第三季度報告，其所載財務報告根據中國企業會計準則編製，並且未 經審計。 承董事會命 深圳市海普瑞藥業集團股份有限公司 董事長 李鋰 中國深圳 二零二五年十月三十日 於本公告 ...

深圳市海普瑞药业集团股份有限公司 2025 年第三季度报告 证券代码：002399 证券简称：海普瑞 公告编号：2025-030 深圳市海普瑞药业集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 3.第三季度财务会计报告是否经过审计 □是 否 1 深圳市海普瑞药业集团股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 1,377,117,225.77 | 11.82% | 4,194,464,397.94 | 3.09% | | 归属于上市公司股东 | 13 ...

Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and has a strong focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][3]. Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms. The company aims to provide high-quality, safe, and effective drugs and services to global patients [2]. - The main business segments of Haiprime include heparin raw materials, downstream low molecular weight heparin products, and biopharmaceutical CDMO services [7]. Financial Performance - For the first half of 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Shareholder Information - As of June 30, 2025, Haiprime had 26,300 shareholders, a decrease of 7.29% from the previous period. The average circulating shares per person remained at 0 [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 29, Haiprime's stock price increased by 0.75%, with a trading volume of 41.3352 million yuan and a turnover rate of 0.28%, bringing the total market capitalization to 17.637 billion yuan [1].

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms and aims to provide high-quality, safe, and effective drugs and services globally [2]. - The main business segments include heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7]. - As of June 30, 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 27, Haiprime's stock rose by 0.84%, with a trading volume of 46.599 million yuan and a market capitalization of 17.622 billion yuan [1]. - The stock has seen a net inflow of 2.6047 million yuan from major investors today, indicating a slight increase in interest [4]. Technical Analysis - The average trading cost of the stock is 11.56 yuan, with the current price fluctuating between resistance at 12.80 yuan and support at 11.53 yuan, suggesting potential for range trading [6].